The case for a drug with this behaviour (acquired life long burden) being regulated price, would be high. It's already capable of being synthesised by compoundi

The case for a drug with this behaviour (acquired life long burden) being regulated price, would be high. It's already capable of being synthesised by compounding pharmacists so I think we're beyond arguing Novo nordisk and the others are vital for production purposes. It's all about IPR and longterm drug development motivations. If we accept some corporate lawfare, the other side of it, Indian pharma would be making this fo 10c per patient per dose. IPR is hard. So many reasons not to override, such a compelling story to revisit why we privatise drug research. (I skimmed the paper. It says we need to be mindful not to overstate the upsides per patient, medically, economically or socially, and that avoided socialised costs at scale here remain conjectural. That said, I still believe they exist)